Prosecution Insights
Last updated: October 04, 2026
Application No. 17/792,196

AN ADHESIVE BODY DRESSING AND METHOD FOR MANUFACTURING AN ADHESIVE BODY DRESSING

Non-Final OA §102§103
Filed
Jul 12, 2022
Priority
Jan 17, 2020 — FI 20205047 +1 more
Examiner
TRUONG, QUANGLONG N
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Dermeco OY
OA Round
3 (Non-Final)
79%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
516 granted / 655 resolved
+18.8% vs TC avg
Strong +24% interview lift
Without
With
+23.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
54 currently pending
Career history
693
Total Applications
across all art units

Statute-Specific Performance

§101
4.5%
-35.5% vs TC avg
§103
55.4%
+15.4% vs TC avg
§102
10.7%
-29.3% vs TC avg
§112
18.0%
-22.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 655 resolved cases

Office Action

§102 §103
DETAILED ACTION Status of Application Claims 1-16 are cancelled. Claims 17-32 are included in the prosecution. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments/Amendments Applicant’s amendments and arguments filed 6/15/2026 are sufficient to withdraw the previous rejections under 35 USC 103 over the teachings of Rolf. However, Examiner additionally incorporates Chen (CN205836154U) in a new ground of rejection, therefore this action is made NON-FINAL. Claim Rejections - 35 USC §102/103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 17-32 are rejected under 35 U.S.C. 103 as obvious over Ma (CN208339669U Machine English Translation) in view of Chen et al. (CN205836154U) hereinafter Chen. Regarding claims 17-32, Ma is drawn to a medical dressing that promotes rapid wound healing. Its structure includes four layers, from bottom to top: a polyurethane film backing layer, a hydrocolloid layer adhered to the polyurethane film backing layer, a functional nonwoven fabric layer adhered to the hydrocolloid layer, and a release paper layer adhered to the functional nonwoven fabric layer; the functional nonwoven fabric layer is a water-soluble chitosan fiber nonwoven fabric or an alginate fiber nonwoven fabric. The dressing provided by this utility model is soft in texture, has strong hydrophilicity, obvious self-dissolving debridement effect, is waterproof, breathable, antibacterial, heat-insulating, does not stick to the wound surface, reduces the number of dressing changes, has low production cost, fast wound healing speed, is simple to prepare, and is easy to industrial production and promotion (abstract). Ma discloses a medical dressing that promotes rapid wound healing, comprising four layers, from bottom to top: a polyurethane film backing layer, a hydrocolloid layer adhered to the polyurethane film backing layer, a functional nonwoven fabric layer adhered to the hydrocolloid layer, and a release paper layer adhered to the functional nonwoven fabric layer; the functional nonwoven fabric layer is a water-soluble chitosan fiber nonwoven fabric or an alginate fiber nonwoven fabric [0007]. Ma also discloses a hydrocolloid dressing and its preparation method [0004]. Ma discloses a polyurethane film backing layer 1 with a thickness of 0.02-0.03 mm; a hydrocolloid layer 2 with a thickness of 0.3-1.2 mm, preferably 0.46-0.85 mm; and a functional nonwoven fabric layer made of commercially available water soluble chitosan fiber nonwoven fabric or alginate nonwoven fabric [0020]. Ma discloses the hydrocolloid layer is a hydrophilic polymeric rubber elastomer layer containing sodium carboxymethylcellulose (NaCMC) and gelatin. It also contains elastic polymers and adhesives, which are commercially available materials. When placed on the polyurethane film backing layer, it ultimately forms an absorbent, self-adhesive, and waterproof dressing sheet that is opaque or translucent, biodegradable, and has good adhesion. At the same time, the hydrocolloid layer can maintain a good moist environment, promoting fibrinolysis, angiogenesis, and wound healing [0018]. Ma does not explicitly disclose biodegradable. However, Chen discloses a biodegradable packaging material, which includes, from the inside out, a rigid material layer, a biodegradable layer, and a printed support layer. The rigid material layer is a polyester film or a polystyrene film, the biodegradable layer is a biodegradable film, and the printed support layer is a polyurethane material. One side of the biodegradable layer is bonded to the rigid material layer by a colloidal adhesive, and the other side of the biodegradable layer is bonded to the printed support layer by a solvent-based adhesive (abstract). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Ma with the teachings of Chen, to arrive at the instant invention. One of ordinary skill in the art would have been motivated to do so because Ma and Chen are in the field of adhesives. Further, one having ordinary still in the art would reasonably expect success in combining prior art elements according to known methods to yield predictable results, see MPEP 2141. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to QUANGLONG N TRUONG whose telephone number is (571) 270-0719. The examiner can normally be reached on 8:00 am-5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A Wax can be reached on 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /QUANGLONG N TRUONG/Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Jul 12, 2022
Application Filed
Aug 22, 2025
Non-Final Rejection mailed — §102, §103
Nov 21, 2025
Response Filed
Mar 18, 2026
Non-Final Rejection mailed — §102, §103
Jun 15, 2026
Response Filed
Aug 31, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12721934
CATIONIC NANODRUG, PREPARATION METHOD THEREFOR, AND DRUG-LOADED IMPLANTABLE MEDICAL DEVICE
4y 6m to grant Granted Sep 01, 2026
Patent 12721815
FREEZE-DRIED EXOSOME COMPOSITION AND USES THEREOF
3y 7m to grant Granted Sep 01, 2026
Patent 12691055
INCRETIN ANALOG-CONTAINING COMPOSITIONS AND USES THEREOF
2y 10m to grant Granted Jul 28, 2026
Patent 12678387
COMPOSITION FOR ALLEVIATING HAIR LOSS OR PROMOTING HAIR GROWTH
3y 11m to grant Granted Jul 14, 2026
Patent 12678411
Nanoformulations of Pazopanib, Compositions Comprising the Same and Methods of Treating Osteoarthritis
2y 7m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
79%
Grant Probability
99%
With Interview (+23.6%)
2y 3m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 655 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month